ONN^® - OncLive News Network^®

Expert oncologists reflect on recent clinical trial data to elucidate the evolving treatment landscape of checkpoint inhibition in non–small cell lung cancer.

Experts discuss current and investigational antibody drug conjugates (ADCs) in non-small cell lung cancer treatment and how they affect therapy approaches.

Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.

Vijayakrishna Gadi, MD, PhD, provides an overview of recent advancements in the treatment of HER2+ metastatic breast cancer with special consideration for challenges in the management of patients with CNS metastases.

Jae Park, MD, reviews the current treatment landscape and emerging options for treating adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Join us LIVE at this year's 2022 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Experts Joyce A. O’Shaughnessy, MD, and Sara A. Hurvitz, MD, provide comprehensive updates on the optimal workup and management of patients with breast cancer.

Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.

How ctDNA testing is being investigated and used in pancreatic and colorectal cancer in the era of precision medicine.

Two experts lead a discussion about chronic lymphocytic leukemia (CLL), focusing on updates in management and special considerations when treating with BTK inhibitors.

Drs Carl M. Gay and Jared Weiss highlight novel treatment advances for newly diagnosed and relapsed/refractory small cell lung cancer.

Hossein Borghaei, DO, MS, and Martin Reck, MD, PhD, highlight recent advances and use of immune checkpoint inhibitors in the treatment of first-line metastatic non-small cell lung cancer.

Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.

Gary Ulaner, MD, PhD and Jeremy Force, DO discuss the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18F-FES-PET imaging in diagnosis and treatment of ER-positive breast cancer and in improving patient outcomes.

Experts review key updates in multiple myeloma management from the ASH 2021 annual meeting.

As part of its Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about the National Comprehensive Cancer Network guidelines and what they mean for patients.

Experts Sandra M. Swain, MD, and Zahi Mitri, MD, MS, reflect on HER2-low breast cancer as a subset of disease and discuss novel therapeutic agents that may improve patient outcomes in this setting.